Procter & Gamble (PG) is back in focus after extending its dividend growth streak to 70 consecutive years and announcing a $3.8 billion deal for health focused company Thorne.

Over the past year, Procter & Gamble’s share price return has been relatively muted compared with its long dividend record and expansion plans. Its 1-year total shareholder return declined 3.41%, and its 5-year total shareholder return was 13.13%, which may suggest fading momentum despite the Thorne acquisition and a recent dividend increase.

If P&G’s latest move into health has caught your attention, it can be a good moment to widen your watchlist with other healthcare related growth ideas through the 44 healthcare AI stocks

Procter & Gamble now trades at a discount to both analyst targets and some intrinsic estimates, even after the Thorne deal headlines. The question is where a reasonable fair value might sit within that spread.

Most Popular Narrative: 34.2% Overvalued

On the most followed valuation narrative, Procter & Gamble’s last close of $144.26 sits well above an implied fair value of about $107.50. This helps frame the recent weakness despite solid fundamentals.

Procter & Gamble operates within a very competitive environment. However, its higher operating margins and wide moat are a clear sign it still operates with competitive advantages over its competitors, as well as having the capability of raising prices if needed. Also, it's always good to see that it still returns on its investments (ROIC) double its cost of capital, showing good capital allocation by management.

This narrative leans heavily on stable margins, steady but modest revenue expansion, and a valuation framework that blends cash flows, earnings power, and long term dividend math. The key pieces lie in how those assumptions interact across different scenarios.

Result: Fair Value of $107.52 (OVERVALUED)

However, this overvalued narrative for Procter & Gamble could be challenged by shifts in competitive intensity or by changes in investor appetite for lower volatility cash flows.

Another View On Procter & Gamble’s Valuation

While the leading narrative prices Procter & Gamble at about $107.50 per share, our DCF model points in the opposite direction. It suggests fair value closer to $201.56, which frames the current $144.26 price as undervalued. Which set of assumptions feels more realistic to you?

For readers who want to see how that result is built line by line, it can help to walk through the SWS DCF model inputs and stress test them for yourself through the Look into how the SWS DCF model arrives at its fair value.

Next Steps

With Procter & Gamble drawing mixed signals on value, it helps to move quickly, review the underlying data yourself, and weigh both sides of the story through the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Procter & Gamble?

Round out your view on Procter & Gamble by lining it up against other opportunities so you can see where it really stands in your portfolio.

• Target dependable income by scanning companies built around robust payouts through the 11 dividend fortresses
• Spot potential value opportunities before they are widely talked about with the screener containing 18 high quality undiscovered gems
• Prioritize resilience and sleep easier through market swings by focusing on companies in the 88 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.